FDA approved Icotyde (icotrokinra) on March 17, 2026 for moderate-to-severe plaque psoriasis in patients 12 and older weighing at least 40 kilograms, per the agency's 2026 novel drug approvals list — the latest entry in the shift from injected biologics toward daily pills for a disease once treated mainly with creams and phototherapy.
This article publishes information, not medical advice. Psoriasis treatment choice depends on disease extent, joint involvement, other medications, and insurance coverage — decide with a dermatologist.
What is icotrokinra and how does it work?
Icotrokinra is an oral selective inhibitor of the IL-23 receptor, blocking a signaling pathway central to the inflammation that drives psoriasis plaques. That target was previously reachable only through injected biologics such as risankizumab and guselkumab, which are highly effective but require needles, refrigeration, and specialty pharmacy logistics. A pill changes the calculus for patients who delay or refuse injections.
Related stories: FDA Approved Utebzi, the First Oral Carbapenem, for Complicated UTIs · FDA Approved Lipfendra, the First Oral PCSK9 Inhibitor, for High LDL.
How big is the oral-versus-injected shift?
Psoriasis affects roughly 3 percent of US adults, and moderate-to-severe disease — several percent of body area or involvement of visible sites — historically justified systemic therapy. The category heated up quickly: the same week, FDA also approved Lynavoy (linerixibat) for cholestatic itching in primary biliary cholangitis, and oral JAK and TYK2 inhibitors have been carving market share from biologics since 2022. Icotrokinra extends the trend to the IL-23 axis, long considered the highest-efficacy target in the disease.
What should patients weigh?
Three things. Efficacy data in the prescribing information — ask how the trial's skin-clearance percentages compare with injected IL-23 blockers. Safety monitoring requirements, since systemic oral agents carry class-specific warnings that topical treatments do not. And coverage: biologics already sit on specialty tiers with prior authorization, and new orals often start there too, so ask your plan whether the pill beats the injection on your out-of-pocket math before switching.
What to watch next
Real-world discontinuation rates will tell the story the trials cannot — whether patients stay on the pill longer than they stayed on the injection. Watch dermatology guideline updates over the next year and the 2027 formulary season, when payers decide where icotrokinra sits relative to the biologics it will compete against.
For more context, read FDA Approved Lipfendra, the First Oral PCSK9 Inhibitor, for High LDL.
For more context, read utebzi fda approval.
For more context, read foundayo fda approval.